New oral anticoagulants in acute coronary syndrome: Is there any advantage over existing treatments?

International Cardiovascular Research Journal

Volumn 8, Issue 3, 2014, Pages 124-126

  Messori, Andrea ^a   Fadda, Valeria ^a   Gatto, Roberta ^a   Maratea, Dario ^a   Trippoli, Sabrina ^a  

^a ESTAV Toscana Centro   (Italy)

Author keywords

Acute Coronary Syndrome; Anticoagulants; Rivaroxaban; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; RIVAROXABAN; TICAGRELOR;

ACUTE CORONARY SYNDROME; ARTICLE; CONFIDENCE INTERVAL; DRUG EFFICACY; HUMAN; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICAL SIGNIFICANCE; THERAPEUTIC EQUIVALENCE;

EID: 84903381940     PISSN: 22519130     EISSN: 22519149     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Dobesh PP, Beavers CJ, Herring HR, Spinler SA, Stacy ZA, Trujillo TC. Key articles and guidelines in the management of acute coronary syndrome and in percutaneous coronary intervention: 2012 update. Pharmacotherapy. 2012;32(12):e348-86.
2. Updated ESC Guidelines for managing patients with suspected non-ST-elevation acute coronary syndromes. Eur Heart J. 2011;32(23):2909-10.
3. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054.
4. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J. 2013;34(22):1670-80.
5. Gatto R, Fadda V, Maratea D, Trippoli S, Messori A. New oral anticoagulants in acute coronary syndrome: a network meta-analysis. [updated 2014; cited]; 2014 Available from: http://www.bmj.com/content/338/bmj.b1180/rr/679758
6. Ahn S, Park SH, Lee KH. How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research. Radiology. 2013;267(2):328-38.
7. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19.
8. Messori A, Fadda V, Maratea D, Trippoli S. Outcomes with short-term versus long-term antiplatelet dual therapy after drug-eluting stenting: quantifying the equivalence margins. Int J Cardiol. 2014;172(2):469-70.
9. Verheugt FW. Combined antiplatelet and novel oral anticoagulant therapy after acute coronary syndrome: is three a crowd? Eur Heart J. 2013;34(22):1618-20.